BeOne Medicines (BEIGF) Depreciation and Depletion (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Depreciation and Depletion data on file, last reported at $39.4 million in Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $39.4 million, up 24.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $139.4 million (down 20.1% YoY), and the FY2025 annual result was $131.6 million, down 21.16% from the prior year.
• Depreciation and Depletion climbed to $39.4 million in Q1 2026 per BEIGF's latest filing, from $34.4 million in the prior quarter.
• Over five years, Depreciation and Depletion peaked at $70.0 million in Q3 2024 and troughed at $14.5 million in Q2 2022.
• A 5-year average of $28.3 million and a median of $23.8 million in 2024 frame the typical range for Depreciation and Depletion.
• The sharpest annual moves came in 2024 and 2025: Depreciation and Depletion soared 263.93% in 2024, then slumped 48.98% in 2025.
• A 5-year view of Depreciation and Depletion shows it stood at $17.0 million in 2022, then grew by 22.38% to $20.9 million in 2023, then soared by 135.1% to $49.0 million in 2024, then fell by 29.83% to $34.4 million in 2025, then climbed by 14.43% to $39.4 million in 2026.
• Business Quant data shows BEIGF's Depreciation and Depletion at $39.4 million in Q1 2026, $34.4 million in Q4 2025, and $35.7 million in Q3 2025.